The company has acquired a SHP2 inhibitor and an ERK inhibitor through two worldwide licensing agreements and has begun testing the former in the clinic.
Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.
Artios can receive $30 million in up-front and near-term payments, and up to $860 million per target if Merck KGaA exercises its exclusive development rights.